Table 2. Peptides used in the study.
Peptide | Sequence | %TFE required for helical structure |
---|---|---|
J14.0i | ASREAKKQVEKALEa | 40 |
J14.1i | ASREAKKKVEADLA | 40 |
J14.2i | ASREAKKQVEKDLA | 40 |
J14.4i | ASREAKKQLEAEHQ | 20 |
J14.29i | ASRAAKKDLEAEHQ | >50 |
J14.8i | ASRAAKKELEAEHQ | >50 |
J14.12i | ASRAAKKELEAKHQ | 40 |
J14.36i | ASRAAKKELEANHQ | 40 |
J14.53i | GSRAAKKELEAKHQ | 20 |
J14.57i | ASRAAKKELEAKHQ | 40 |
J14.0i | KQAEDKVKASREAKKQVEKALEQLEDKVK | |
J14.1i | KQAEDKVKASREAKKKVEADLAQLEDKVK | |
J14.2i | KQAEDKVKASREAKKQVEKDLAQLEDKVK | |
J14.4i | KQAEDKVKASREAKKQLEAEHQQLEDKVK | |
J14.29i | KQAEDKVKASRAAKKDLEAEHQQLEDKVK | |
J14.8i | KQAEDKVKASRAAKKELEAEHQQLEDKVK | |
J14.12i | KQAEDKVKASRAAKKELEAKHQQLEDKVK | |
J14.36i | KQAEDKVKASRAAKKELEANHQQLEDKVK | |
J14.53i | KQAEDKVKGSRAAKKELEAKHQQLEDKVK | |
J14.57i | KQAEDKVKASRAAKKELEAKHQAQLEDKVK |
a The underlined section of each 14mer peptide indicates predicted α-helical structure, as determined by PSIPRED.